APPLIED GENETIC TECHNOLOGIES

Applied Genetic Technologies is a biotechnology company that uses a proprietary gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. The company focuses on the field of ophthalmology, where it has clinical programs in X-linked retinoschisis, X-linked retinitis pigmentosa, and achromatopsia and a preclinical program in optogenetics. In addition, the company has preclinical programs in adrenoleukodystrophy, which is a disease of the central nervous system and several programs in otology. The company also developed technological capabilities in the design, construction and manufacture of viral vectors using adeno-associated virus technology.
  • TickerAGTC
  • ISINUS03820J1007
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

ValuEngine Rating and Forecast Report for AGTC

ValuEngine Rating and Forecast Report for AGTC

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Wedbush Research

Wedbush Morning Call - Aug 15

ValuEngine Rating and Forecast Report for AGTC

ValuEngine Rating and Forecast Report for AGTC

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Wedbush Research

Wedbush Morning Call - Aug 15

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Insider bought: A director bought 3,000 shares at 9.625USD and

A director at Applied Genetic Technologies Corp bought 3,000 shares at 9.625USD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rule...

ValuEngine Rating and Forecast Report for AGTC

ValuEngine Rating and Forecast Report for AGTC

ValuEngine Rating and Forecast Report for AGTC

ValuEngine Rating and Forecast Report for AGTC

ValuEngine Rating and Forecast Report for AGTC

ValuEngine Rating and Forecast Report for AGTC

ValuEngine Rating and Forecast Report for AGTC

ValuEngine Rating and Forecast Report for AGTC

ValuEngine Rating and Forecast Report for AGTC

ValuEngine Rating and Forecast Report for AGTC

ResearchPool Subscriptions

Get the most out of your insights

Get in touch